Moderna, Inc. vs Petróleo Brasileiro SA — how do they compare? Moderna, Inc. trades at $62.15 (market cap $24.18B), while Petróleo Brasileiro SA trades at $17.91 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 4.6× Moderna, Inc.'s market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PBR | |
|---|---|---|
Market Cap | $24.18B | $112.19B |
Sector | Health | Technology |
52-Week High | $81.80 | $22.03 |
52-Week Low | $22.36 | $11.54 |
Enterprise Value | $20.33B | $172.61B |
Dividend Yield | — | 9.42% |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Petrobras (PBR) trades at $17.93, down 2.18% today, showing strong fundamentals with a P/E of 4.53 and robust profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $1.60 versus $1.40 expected, driven by record production and higher oil prices. Technical indicators signal bearish momentum, with RSI at oversold levels near 20.31, while analyst consensus remains positive with 50% buy ratings.
The outlook remains favorable due to cheap valuations and production growth, but risks include regulatory uncertainty and volatile oil prices. Investment opportunity lies in sustained dividend payments and operational efficiency, though geopolitical and macroeconomic factors could pressure near-term performance.
Trailing returns across standard periods
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →